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Abstract 
Context: The corpus luteum (CL) secretes prorenin, renin’s inactive precursor. It may thus contribute to 
the renin-angiotensin-aldosterone-system (RAAS) activation that is required for maternal adaptation in 
pregnancy. Whether this activation is disturbed in pregnancies lacking a CL is unknown.
Objective: The objective of this work is to investigate maternal RAAS determinants in early pregnancy.
Design and Setting: Two observational prospective cohort studies took place  at 2 tertiary referral 
hospitals.
Patients and Intervention(s): Pregnancies (n = 277) were stratified by CL number and in vitro fertilization 
(IVF) protocol: 0 CL (programmed cycle frozen embryo transfer [FET], n = 28), 1 CL (natural cycle FET, 
n  =  41 and spontaneous conceptions, n  =  139), and more than 1 CL (ovarian stimulation and fresh 
embryo transfer, n = 69).
Methods: Quantification was performed for maternal prorenin, renin, and aldosterone blood levels at 5, 
9, and 11 weeks of gestation.
Results: Prorenin and renin were lower in the absence of a CL at all time points when compared to 1 CL, 
whereas prorenin, renin, and aldosterone were higher in the presence of more than 1 CL vs 1 CL (P < .05). 
Ovarian stimulation with menopausal gonadotropin resulted in higher prorenin, renin, and aldosterone 
concentrations during the late first trimester than recombinant follicle-stimulating hormone (P <  .05). 
Prorenin, and to a lesser degree renin, correlated positively with serum progesterone and relaxin, but not 
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antimüllerian hormone (AMH) were additional determinants of circulating prorenin. Finally, pregnancies 
conceived in the absence of a CL were more disposed to develop preeclampsia.
Conclusions: CL number, IVF protocol, BMI, PCOS, and AMH affect maternal RAAS activation in early 
pregnancy, and may thus contribute to pregnancy complications.
Freeform/Key Words:  renin-angiotensin-aldosterone-system, in  vitro fertilization, corpus luteum, pregnancy, 
prorenin, preeclampsia
An optimal ovarian endocrine function is of vital import-
ance for normal reproductive health and the establishment 
of pregnancy. Essential in early pregnancy is proper corpus 
luteum (CL) function, a unique temporary endocrine struc-
ture in the ovary. The CL is a major source of reproductive 
hormones in the periconceptional period and in early preg-
nancy before the endocrine function of the placenta be-
comes sufficiently developed to supersede it (1).
In addition to sex steroids such as estrogens, andro-
gens, and progestagens, which are indispensable for endo-
metrial development, implantation, placentation, and 
pregnancy maintenance, the CL produces important vaso-
active factors like relaxin and prorenin (2, 3). Relaxin is a 
vasodilator that simultaneously contributes to cardiovas-
cular and renal adaptation in pregnancy (4, 5). Prorenin, 
the precursor of renin, is not only released by the CL, but 
also during maturation of the ovarian follicle (6). Given its 
local synthesis, it is generally believed that there is an inde-
pendent ovarian renin-angiotensin-system (RAS), resulting 
in high local angiotensin II concentrations (7, 8). Strikingly, 
ovarian prorenin is also released into the circulation, and 
may thus be part of the well-known RAS activation in the 
maternal circulation during early gestation (3, 9). Such 
RAS activation likely contributes to the maternal cardio-
vascular and hemodynamic adaptations of pregnancy 
because angiotensin II is an important blood pressure regu-
lator with major effects on fluid and electrolyte balance, 
in part through aldosterone (“RAAS,” renin-angiotensin-
aldosterone-system) (10).
Conrad and Baker have proposed that the CL is an im-
portant regulator of the maternal physiologic adaptation 
to pregnancy (1). Indeed, remarkable differences in cardio-
vascular, renal, and plasma volume regulation, particularly 
during early pregnancy, were reported between pregnan-
cies conceived spontaneously and after in vitro fertilization 
(IVF) treatment, but also between the 2 main types of IVF 
treatment involving either controlled ovarian stimulation 
(COS) in the presence of multiple CL or hypothalamic-
pituitary suppression in absence of CL (11-14). IVF preg-
nancies are more frequently complicated by early and late 
vascular-related pregnancy complications compared to 
spontaneously conceived pregnancies (15, 16). Lately, in 
prospective and registry-based studies an increased risk of 
preeclampsia has been observed after programmed frozen 
embryo transfer (FET) that involved ovarian suppression 
and absence of a CL (17, 18). Taken together, these data 
support the importance of CL-derived endocrine factors, 
including those contributing to the ovarian RAS, in ma-
ternal vascular health during early pregnancy.
In light of frequent utilization of IVF treatment, more 
knowledge is needed about the impact of such treatment 
on ovarian endocrine function associated with the early 
adaptation to pregnancy to provide the safest treatment to 
patients and to improve maternal and perinatal outcome 
following IVF. From this background, we hypothesize that 
IVF treatment and fertility-specific characteristics like poly-
cystic ovary syndrome (PCOS), body mass index (BMI), 
and antimüllerian hormone (AMH) affect periconception 
ovarian biology at least in part by modulating RAAS ac-
tivation. Accordingly, the first aim of this study was to in-
vestigate maternal RAAS determinants in early pregnancy. 
To address this question, we used 2 large periconception 
cohorts, the Stanford Pregnancy Outcomes Following 
Infertility (POFI) Study and the Rotterdam Periconceptional 
Cohort (Predict) Study (19, 20). Importantly, von Versen-
Höynck et al have shown in the POFI Study that an ab-
normal CL number associates with increased preeclampsia 
risk (14). Since such pregnancy outcome data have not 
been linked to CL number in the Predict Study, our second 
aim was to confirm this relationship in the Predict cohort.
Materials and Methods
Stanford Pregnancy Outcomes Following 
Infertility Study
Participants were part of the Stanford Pregnancy 
Outcomes Following Infertility (POFI) Study (19). After 
approval of the study by the institutional review board 
at Stanford University, 878 infertile patients undergoing 
treatment at the Stanford Division of Reproductive 
Endocrinology and Infertility with sonographically con-
firmed viable pregnancy were recruited at 8 weeks’ gesta-
tion between October 2011 and March 2014. A subcohort 
of 80 randomly chosen participants was selected for the 
analysis performed in this study. Informed consent was 
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samples for research purposes. One serum sample of each 
pregnancy was collected at 4 to 5 weeks of gestational 
age (GA) initially for the clinical measurement of quan-
titative human chorionic gonadotropin (hCG), and rem-
nant serum not required for clinical testing was stored 
at –80°C for later analysis. Quantification of relaxin, 
progesterone, and estradiol in these samples has been 
reported before (21). At the time of study entry, partici-
pants provided information about age, parity, ethnicity, 
and other demographic and clinical data using a stand-
ardized questionnaire. Maternal BMI, blood pressure, 
and AMH were determined when patients were admitted 
to the fertility clinic. Prenatal care and delivery records 
were collected from the obstetricians and hospitals that 
provided care for each patient.
Assisted reproduction protocols. Standard protocols 
were used for COS and fresh embryo transfer 
(ET) and FET. IVF patients received a protocol of 
leuprolide acetate (gonadotropin-releasing hormone 
[GnRH]-antagonist), or microdose leuprolide acetate 
and administered gonadotropins for COS. Embryo 
cryopreservation was performed almost always (> 95%) 
at the blastocyst stage. All FET cycles were monitored 
by ultrasound until the endometrium reached 7 mm or 
larger. For modified natural-cycle FETs, when the lead 
follicle reached 18  mm, hCG was administered in the 
evening, and ET was typically performed 7  days later. 
If a luteinizing hormone (LH) surge was detected by 
serum LH or an ovulation predictor kit, the transfer 
was performed 6  days after detection of the LH 
surge. Vaginal progesterone supplementation was 
used routinely. Programmed FET cycles used estradiol 
(administered orally or transdermally) and vaginal and/
or intramuscular progesterone. Absence of a developing 
follicle was confirmed by ultrasound for all programmed 
FET cycles. Spontaneous pregnancies were among women 
with known subfertility. GA in spontaneously conceived 
pregnancies was calculated based on the first day of the 
last menstrual period (LMP) or if known the ovulation 
date in spontaneously conceived pregnancies. After fresh 
ET GA was calculated using the ovum pick-up day plus 
14 days and in pregnancies after FET, GA was defined as 
the transfer date plus 17 days for cleavage-stage embryos 
or plus 19 days for blastocyst transfers.
Rotterdam Periconceptional Cohort Study 
(Predict Study)
Participants were part of the Rotterdam Periconception co-
hort (Predict Study), an ongoing prospective, periconception 
cohort at the Department of Obstetrics and Gynecology of 
the Erasmus MC, University Medical Center, in Rotterdam, 
the  Netherlands (20). This cohort enrolled a subcohort 
of 241 women between January  2017 and March 2018 
with a focus on the (patho)physiology of early placental 
development. The Predict Study was conducted in accord-
ance with the ethical principles for medical research set 
out in the Declaration of Helsinki and was approved by 
the medical ethical assessment committee of the Erasmus 
MC. Inclusion criteria are a minimum maternal age of 
18 years or older, with an ongoing intrauterine singleton 
pregnancy of less than 100 weeks of gestation. Exclusion 
criteria for the present study are pregnancies ending in mis-
carriages, oocyte donation, withdrawal, and fetuses or neo-
nates with congenital malformations. The study involves 
questionnaires at study entry and throughout gestation, 
serial 3-dimensional ultrasound measurements, and serial 
blood withdrawal (EDTA tubes) at 9 and 11 weeks’ GA. 
Maternal blood pressure, weight, and height were meas-
ured at the study entry visit. Infertility diagnosis, treatment, 
and clinical measurement of quantitative AMH in serum 
was obtained from medical records. Written informed con-
sent was obtained from all study participants and partner 
at enrollment.
Assisted-reproduction protocols. Standard protocols 
were used for COS, ovum pick-up, IVF treatment, and 
assessment of embryo morphology (22, 23). IVF patients 
received either GnRH agonists (Decapeptyl or Lucrin) or 
antagonists (Orgalutran, Cetrotide, or Fyremadel). Women 
received COS with either Menopur, a highly purified, 
urine-derived, human menopausal gonadotropin (hMG, 
containing follicle-stimulating hormone [FSH], LH, and 
hCG) or recombinant human (rh)FSH (Bemfola, Gonal-F, 
or Rekovelle). For modified natural-cycle FETs, a frozen-
thawed ET was performed 4  days after spontaneous 
ovulation, detected by urinary LH testing. In programmed 
FET cycles the endometrium was prepared using estrogens 
followed by increasing dosages of intravaginal progesterone 
and daily injections of a GnRH agonist. All FET cycles 
were monitored by ultrasound until the endometrium 
reached 4  mm or larger. Transfer of the frozen-thawed 
embryo occurred after 15 days of endometrial preparation. 
Spontaneous pregnancies in this cohort occurred in women 
with and without known subfertility. GA was calculated 
based on the first day of LMP in spontaneously conceived 
pregnancies or the ovum pick-up day plus 14  days for 
pregnancies after fresh ET. In pregnancies after FET, 
GA was defined as the transfer date plus 19  days. In 
case of an irregular menstrual cycle, unknown LMP, or 
the GA based on LMP deviated more than 6  days from 
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Classification of the 2 study groups
Participants were grouped according to CL number at con-
ception: (1) 0 CL, from FET in a programmed cycle, (2) 1 
CL, spontaneous conceptions, including intrauterine insem-
ination (IUI) and hormonal treatment or FET in a modi-
fied natural ovulatory cycle, (3) more than 1 CL, ovarian 
stimulation with fresh ET. The CL status at conception in 
pregnancies conceived by fresh ET is based on number of 
retrieved eggs during ovum pick-up (median: 11.0 [inter-
quartile range, 7-16]).
Renin, prorenin, and aldosterone 
measurements
All measurements were performed at the Department of 
Internal Medicine of the Erasmus MC, making use of ei-
ther serum (POFI Study) or EDTA plasma (Predict Study). 
Renin and prorenin concentrations were measured by an 
immunoradiometric assay (Cisbio) using an active site-
directed radiolabeled antibody that recognizes renin only. 
Prorenin concentrations are calculated by subtracting renin 
from total renin measured after activating prorenin with 
aliskiren (24). Aldosterone concentrations were measured 
by solid-phase radioimmunoassay (Demeditec Diagnostics).
Hypertensive pregnancy outcomes in the 
Predict Study
To verify whether the previously observed increased rate 
of preeclampsia in pregnancies conceived in the absence 
of a CL (14) also applies to the Predict Study, we ana-
lyzed clinical hypertensive pregnancy outcomes according 
to number of CL in participants included between January 
2012 and December 2016 in this cohort. Postpartum 
filled-out questionnaires were checked with medical re-
cords. Hypertensive disorders were defined according 
to the current American Congress of Obstetricians and 
Gynecologists guidelines (25).
Statistical analysis
Data are presented as mean ± SD for normal distributed vari-
ables and median and interquartile range for skewed vari-
ables. Analysis was performed by analysis of variance and 
Kruskal-Wallis test, respectively. Categorical characteristics, 
described using frequencies (proportions), were compared 
by chi-square test. Log-transformed RAAS component con-
centrations in the various groups were compared by Mann-
Whitney U test. Based on a previous study by Verdonk and 
colleagues (26) on RAAS component levels in pregnant 
women, a minimum number of 8 per group was calculated 
to be sufficient to detect a 50% difference in renin, prorenin, 
and aldosterone with 80% power and 5% significance. 
Spearman ρ rank correlation coefficient (R) was used to 
evaluate correlations between hormonal levels. The relation-
ship between fertility-specific characteristics—BMI, PCOS, 
AMH, number of follicles, retrieved oocytes on the punction 
date after ovum pick-up, and total follicle diameter (deter-
mined the day of ovulation triggering, and representing the 
sum of the diameters of all follicles), and prorenin concen-
tration— was studied by multivariable linear regression ana-
lysis after adjusting for relevant confounders (CL number, 
maternal age, BMI, stimulation treatment, and/or treat-
ment dose). Hypertensive pregnancy outcomes were ana-
lyzed by CL number and compared by the chi-square test. 
Multivariable logistic regression was used with preeclampsia 
as outcome variable and CL number as predictor. The model 
was adjusted for maternal age, BMI, parity, smoking, and 
chronic hypertension. All analyses were performed using R 
(R for Windows, version 3.5; R Core Team). A P value of less 
than .05 was considered significant.
Results
Baseline characteristics
For this study 80 participants from the POFI Study were 
included and 241 pregnancies from the Predict Study were 
enrolled. After excluding 27 pregnancies ending in miscar-
riage, 8 with congenital malformation, 4 from oocyte do-
nation, and 5 for which blood was not available in the first 
trimester, 75 (POFI) and 202 (Predict) pregnancies were eli-
gible for analysis. Table 1 shows for both study groups the 
maternal baseline characteristics stratified for CL number 
at the moment of conception. All CL groups were compar-
able with regard to age, preconception blood pressure, GA 
at the moment of blood draw, ethnicity, and smoking. In 
the Predict Study preconception alcohol use was higher in 
the 0 CL group and the 1 CL group displayed a higher 
BMI. There was a higher rate of nulliparous pregnancies 
in the 0 CL and more than 1 CL groups compared to the 
1  CL group. The Predict Study contained more women 
with PCOS, particularly in the 0 CL group.
First-trimester maternal renin-angiotensin-
aldosterone-system concentrations
Maternal concentrations of renin, prorenin, and aldos-
terone by CL number at conception are presented in Fig. 1. 
Renin and prorenin were significantly lower in the 0 CL 
group at all time points when compared to the 1 CL group. 
Renin, prorenin, and aldosterone at 9 and 11 weeks were 
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compared to 1 CL. Although the same difference was ob-
served for renin and prorenin at 5 weeks, this was not 
significant. Within the 1 CL group, no differences were ob-
served for renin, prorenin, and aldosterone between FET 
in a natural cycle and spontaneous conception (data not 
show). The renin/total renin ratio decreased by increasing 
CL number, although this was significant at 11 weeks only 
when comparing the more than 1 CL group with the 1 CL 
group (P = .01). The renin/total renin ratio was higher in the 
5-week serum samples than in the 9- and 11-week plasma 
samples (P < .001). The lowest renin/total renin ratio was 
observed at 9 weeks in the 7 women in the Predict Study 
who later developed preeclampsia (5.56 [5.39-5.73] vs 8.02 
[6.47-9.76] in the 195 nonpreeclamptic cases; P = .04). The 
aldosterone/renin ratio was lower in the 1 CL group vs the 0 
CL group (P < .05), and increased again in the more than 1 
CL group compared to the 1 CL group (P < .01). Aldosterone 
levels were higher in the more than 1 CL group vs the 1 CL 
group (P < .001). Renin correlated more strongly with al-
dosterone in the more than 1 CL group than in the 1 CL 
group (Fig. 2). In the 0 CL group, no significant correlation 
was observed between renin and aldosterone.
Relaxin, progesterone, and estradiol levels are shown in 
Table 1, and have been derived from a previously published 
Table 1. Baseline demographic and clinical characteristics of Pregnancy Outcomes Following Infertility and Predict Study 
participants by corpus luteum number
POFI Study group 0 CL (n = 20) 1 CL (n = 37) > 1 CL (n = 18) P
Maternal characteristics     
Maternal age, y 34.2 ± 3.8 34.1 ± 4.3 34.3 ± 4.5 .98
GA blood draw, 5 wks, d 28.0 (28.0-29.0) 29.0 (27.0-31.0) 27.0 (27.0-28.8) .08
Nulliparous (n, %) 17 (85.0) 17 (45.6) 15 (83.3) < .01
Ethnicity, (n, % Non-Hispanic or Non-Latino) 18 (90) 36 (97.3) 18 (100) .25
BMI at study entry, kg/m2 23.6 (20.7-26.3) 23.7 (21.0-26.7) 22.4 (19.9-24.9) .50
MAP at study entry 83.2 (6.2) 86.0 (10.6) 84.4 (10.0) .55
PCOS (n, %) 5 (25.0) 0 (0.0) 2 (11.1) .07
Lifestyle    .70
Preconceptional alcohol use (n, %) 1 (8.3) 0 (0.0) 1 (10.0) .36
Preconceptional smoking (n, %) 1 (5.0) 3 (8.1) 2 (11.1) .79
Biochemical measurements     
Relaxin, pg/mL 7.8 (7.8-7.8)a 221 (126-280) 294 (161-448) < .001
Progesterone, ng/mL 5.6 (4.1-8.2) 18 (14-24) 57 (39-103) < .001
Estradiol, pg/mL 194 (146-375) 162 (116-347) 470 (210-755) .05
Preconceptional AMH 3.3 (1.3-7.2) 3.0 (3.0-3.0) 1.8 (1.0-3.5) .70
Predict Study group 0 CL (n = 8) 1 CL (n = 143) >1 CL (n = 51) P
Maternal characteristics     
Maternal age, y 30.5 ± 3.9 32.0 ± 4.4 33.0 ± 4.7 0.25
GA blood draw, 9 wks, d 67.5 (65.5-68.3) 65.0 (64.0-67.5) 66.0 (65.0-67.0) .14
GA blood draw, 11 wks, d 81.5 (79.5-82.3) 79.0 (78.0-82.0) 79.0 (78.0-82.0) .39
Nulliparous (n, %) 6 (75.0) 68(47.6) 42 (82.4) < .01
Ethnicity (n, %)    .24
 Dutch 6 (75.0) 104 (75.4) 46 (90.2)  
 Western 0 (0.0) 5 (3.6) 1 (2.0)  
 Non-Western 2 (25.0) 29 (21.0) 4 (7.8)  
BMI at study entry, kg/m2 21.4 (20.9-22.8) 25.2 (22.6-29.2) 23.9 (21.8-27.4) .02
MAP at study entry 80.8 ± 12.1 80.7 ± 6.8 79.6 ± 7.1 .74
PCOS (n, %) 5 (62.5) 21 (14.7) 15 (29.4) < .01
Lifestyle     
Preconceptional alcohol use (n, %) 5 (62.5) 42 (29.4) 10 (19.6) .04
Preconceptional smoking (n, %) 1 (12.5) 21 (14.7) 5 (9.8) .68
Biochemical measurements     
Preconceptional AMH 4.0 (3.5-7.7) 9.3 (3.9-12.9) 4.2 (2.9-7.0) .32
Data are presented as mean ± SD or median (interquartile range). Relaxin, progesterone, and estradiol levels were available in 47 (19, 16, and 12), 46 (19, 15 and 
12), and 45 (19, 15 and 11) women, respectively.
Abbreviations: AMH, antimüllerian hormone; BMI, body mass index; CL, corpus luteum; GA, gestational age; MAP, mean arterial pressure; PCOS, polycystic 
ovary syndrome; POFI, Pregnancy Outcomes Following Infertility.
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report on a POFI Study subset (21). Relaxin was below the 
detection limit in all women without a CL. Both relaxin 
and progesterone, but not estradiol, correlated significantly 
with renin and prorenin (Fig. 3). Correlations were much 
stronger with prorenin than renin.
Impact of in vitro fertilization protocol on renin-
angiotensin-aldosterone-system concentrations
In the Predict Study IVF patients received diverse drugs for 
COS. Women who conceived with fresh ET after COS with 
hMG (n = 21) showed significantly higher renin, prorenin, 
and aldosterone concentrations at 9 and 11 weeks than 
those stimulated with rhFSH (n = 26; Table 2). There was 
no difference in RAAS component concentrations con-
cerning the use of GnRH (ant)agonists (data not shown), 
nor did the characteristics of the women treated with hMG 
or rhFSH differ (data not shown).
Prorenin determinants: periconceptional 
maternal characteristics and fertility parameters
Given the previously described relationship between 
RAAS parameters and CL number, and because infertility 
Figure 2. Correlations by Spearman rank test between maternal plasma aldosterone and plasma renin concentrations at 11 weeks of gestation in 
women conceived by different numbers of corpora lutea (CL) at conception (11 weeks: 0 CL [n = 8], 1 CL [n = 138], or > 1 CL [n = 46]).
Figure 1. Comparison of maternal renin, prorenin, aldosterone, renin/total renin ratio, and aldosterone/renin ratio concentrations in first trimester of 
pregnancy at 5, 9, and 11 weeks of gestation in women conceived by different numbers of corpora lutea (CL) at conception (5 weeks: 0 CL [n = 20], 1 
CL [n = 37] or > 1 CL [n = 18], 9 weeks: 0 CL [n = 6], 1 CL [n = 70] or > 1 CL [n = 35] and 11 weeks: 0 CL [n = 8], 1 CL [n = 138] or > 1 CL [n = 46]). Boxplots 
present median, 10th, 25th, 75th, and 90th percentiles. Log-transformed renin-angiotensin-aldosterone-system component concentrations in the 
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(requiring IVF treatment) increases with age, we studied 
the association between prorenin and BMI in the entire 
study group after adjusting CL number and maternal age 
(27). This revealed a negative relationship between BMI 
and the prorenin concentrations at 9 and 11 weeks’ ges-
tation (Table 3). When studying the prorenin association 
with AMH and PCOS, we additionally adjusted for BMI 
(on top of CL number and age), given the well-known re-
lationship between BMI, AMH, and PCOS (28, 29). It was 
then found that AMH and PCOS associated positively with 
the prorenin concentrations at 11 weeks (Table 3). Finally, 
using the group with the largest n-number (11-week co-
hort, n = 192), we incorporated all prorenin-determining 
parameters (CL number, BMI, AMH, and PCOS) and age 
Figure 3. Correlations by Spearman rank test between relaxin (n = 47), progesterone (n = 46), estradiol (n = 45), and renin and prorenin concentra-











 user on 16 O
ctober 2020
The Journal of Clinical Endocrinology & Metabolism, 2020, Vol. 105, No. 11 8
into a multiple linear regression model. Under those condi-
tions, only AMH, maternal age, and CL number remained 
independent determinants of log [prorenin] (log [AMH] β: 
.210, P = .035; age β: .033, P = .014; 1 CL group β: .483, 
P = .033; > 1 CL group β: 1.070, P < .001).
In the more than 1 CL group, after adjusting for stimu-
lation method, dose, and maternal age, total follicle diam-
eter prior to ovum pick-up associated positively with 
prorenin concentrations at 11 weeks, albeit not signifi-
cantly (see Table  3). This association became significant 
when excluding women with PCOS. The latter outcome 
was unaltered after additional adjusting for BMI and 
AMH (total follicle diameter β: .542 [95% CI: 0.036-
1.048], P = .037). No linear relation was found between the 
number of follicles or retrieved eggs and maternal prorenin 
concentrations during the first trimester.
Hypertensive pregnancy outcomes in the 
predict study
Of the 868 singleton live birth pregnancies that were 
included between January 2012 and December 2016 in 
Table 3. Determinants of circulating prorenin. Maternal characteristics refer to total study group (0 corpus luteum [CL], 1 CL, 
and > 1 CL), and fertility parameters refer to pregnancies conceived by fresh embryo transfer (> 1 CL group)
 
5 wks’ GA log  
(prorenin), pg/mL
9 wks’ GA log  
(prorenin), pg/mL
11 wks’ GA log  
(prorenin), pg/mL
β (95% CI) P β (95% CI) P β (95% CI) P
Maternal characteristics N = 75  N = 111  N = 192  
Log, BMI, kg/m2a –.307 (–1.043 to .429) .41 –.915 (–1.340 to –.492) < .001 –.786 (–1.096 to –.476) < .001
PCOSb .389 (–.060 to .839) .09 –.028 (–.241 to .186) .80 .157 (.003 to .310) .04
Log AMHb .128 (–.108 to .363) .26 .196 (–.124 to .516) .21 .235 (.035 to .435) .02
Fertility parametersc N = 18  N = 35  N = 46  
No. of follicles –.206 (–1.126 to .714) .64 .148 (–.329 to .624) .52 .318 (–.144 to .780) .17
Total follicle diameter –.128 (–1.085 to .829) .78 .248 (–.201 to .698) .26 .402 (–.004 to .809) .05
No. of oocytes –.198 (–.513 to .117) .21 –.070 (–.416 to .194) .70 –.096 (–.474 to .282) .60
Fertility parameters in non-PCOS N = 16  N = 26  N = 35  
No. of follicles –.108 (–1.087 to .871) .82 .387 (–.310 to 1.083) .25 .472 (–.140, 1.085) .12
Total follicle diameter –.044 (–1.050 to .963) .93 .509 (–.103 to 1.121) .09 .625 (.113 to 1.136) .02
No. of oocytes –.118 (–.442 to .206) .47 –.211 (–.669 to .246) .33 –.224 (–.704 to .257) .34
The table shows the effect estimates of the linear models for the association between maternal characteristics in the total study group and fertility parameters 
during ovum pick-up from pregnancies conceived by fresh embryo transfer (> 1 CL group) and maternal prorenin concentrations at 5, 9, and 11 weeks of gestation.
Abbreviations: AMH, antimüllerian hormone; BMI, body mass index; CL, corpus luteum; GA, gestational age; PCOS, polycystic ovary syndrome.
aModel adjusted for CL number at conception and maternal age.
bModel adjusted for CL number at conception, maternal age, and BMI.
cModel adjusted for stimulation method, dose, and maternal age. Fertility parameters were log-transformed.
Table 2. Maternal renin-angiotensin-aldosterone-system concentrations of pregnancies conceived by fresh embryo transfer 
(> 1 corpora lutea) after controlled ovarian stimulation by gonadotropin used
rhFSH (n = 26) hMG (n = 21) P
9 wks’ GA    
Renin, pg/mL 24.1 (22.2-31.8) 35.7 (29.5-44.5) .01
Prorenin, pg/mL 353 (244-396) 398 (352-533) .03
Aldosterone, pg/mL 394 (327-538) 848 (534-987) .002
Renin/Total renin ratio, ×100 6.92 (5.86-8.87) 7.66 (6.29-8.80) .64
Aldosterone/Renin ratio 17.1 (13.2-20.5) 20.0 (15.4-31.0) .26
11 wks’ GA    
Renin, pg/mL 26.1 (20.5-28.7)  .02
Prorenin, pg/mL 334 (264-409) 401 (333-590) .045
Aldosterone, pg/mL 358 (235-538) 621 (392-1221) .01
Renin/Total renin ratio, ×100 6.52 (5.61-7.65) 6.51 (6.07-7.22) .87
Aldosterone/Renin ratio 13.3 (10.8-24.5) 17.8 (14.0-36.0) .07
Median value (interquartile range) are shown; Mann-Whitney U test was performed.
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the Predict Study, 29 pregnancies conceived in the ab-
sence of a CL, 672 with 1 CL and 167 with multiple CL. 
Women who conceived through COS with fresh ET (> 1 
CL) were more often nulliparous (Table 4). Women who 
conceived with 1  CL displayed a higher preconception 
BMI (24.6  ±  8.5) and smoking status and more often 
had a history of hypertensive disease in previous preg-
nancy. Women who conceived in the absence of a CL 
were slightly older and more often hypertensive before 
pregnancy.
The incidence of developing gestational hypertension, 
preeclampsia, HELLP (hemolysis, elevated liver enzymes, 
and low platelets) syndrome, and eclampsia was higher 
after conception in the absence of a CL compared with 1 
CL and more than 1 CL (Table  5). The multivariate ad-
justed odds ratio for preeclampsia risk in the absence of a 
CL compared with 1 CL was 4.23 (95% CI, 1.17-12.94; 
P = .02).
Discussion
In this combined study of 2 periconception cohorts we 
demonstrate that, during the first trimester, pregnancies 
conceived in the absence of a CL showed lower circu-
lating renin and prorenin concentrations compared to 1 
CL, whereas renin, prorenin, and aldosterone concentra-
tions were higher in the presence of more than 1 CL vs 
1 CL. Additional maternal RAAS determinants in early 
pregnancy were type of ovarian stimulation, BMI, PCOS, 
AMH, and total follicle diameter. Secondly, an abnormal 
CL number associates with increased preeclampsia risk.
RAAS data were consistent at 3 different time points, 
and agree with the concept that prorenin is produced by 
the CL, resulting in higher prorenin levels at higher CL 
numbers (30-32). This also seemed to be the case for renin. 
However, some caveats need to be considered. First, serum 
samples were available for the POFI Study (5 weeks) and 
plasma samples for the Predict Study (9 and 11 weeks), 
while all samples had been stored for more than 12 months 
at –80°C. Depending on the sampling conditions, pH, and 
temperature, prorenin’s conformation may alter from closed 
(with the prosegment covering the active site) to open (with 
the active site being accessible to antibodies applied in the 
renin assay) (33). The consequence of this “nonproteolytic” 
prorenin activation is that some prorenin may be rec-
ognized as renin in the renin immunoradiometricassay, 
thereby artificially elevating renin and lowering prorenin. 
It is important to note that prorenin levels are at least one 
order of magnitude higher than renin levels. Hence, such 
activation has major consequences for renin, but hardly af-
fects prorenin.
To address this issue, we calculated the renin/total renin 
ratio. This ratio differed between serum and plasma sam-
ples, confirming that sampling differences are likely to af-
fect prorenin. The ratio decreased at increasing CL levels at 
all time points. This is suggestive for a relatively higher rise 
in prorenin than renin, but still does not exclude that some 
prorenin is recognized as renin. Therefore, additionally, at 
9 and 11 weeks, we determined the aldosterone/renin ratio. 
This ratio decreased between 0 CL and 1 CL, implying ei-
ther that aldosterone became dependent on factors other 
than renin, or that indeed renin levels were higher. The al-
dosterone/renin ratio increased again in the more than 1 
CL group compared to the 1 CL group. Simultaneously, 
aldosterone levels nearly doubled in women with more 
than 1 CL. Because the renin-aldosterone correlation was 
strongest in the latter group, suggestive for renin (via angio-
tensin II) being the main determinant of this aldosterone 
Table 4. Baseline demographic and clinical characteristics of study participants included January 2012 to December 2016 in 
the Predict Study (n = 868)
Predict Study participants, 2012 to 2016 0 CL (n = 29) 1 CL (n = 672) > 1 CL (n = 167) P
Age, y 34.9 ± 5.1 31.8 ± 4.7 33.4 ± 4.2 < .001
Age > 40 y, (n, %) 2 (8.3) 19 (2.9) 9 (5.7) .10
BMI, kg/m2 22.8 ± 10.3 24.6 ± 8.5 22.8 ± 9.0 .04
BMI > 30, (n, %) 6 (20.7) 127 (18.9) 19 (11.4) .16
Nulliparous, (n, %) 18 (62.1) 254 (37.8) 115 (68.9) < .001
Ethnicity, (n, %)    .28
 Dutch 27 (93.1) 479 (79.8) 127 (78.4)  
 Western 1 (3.4) 29 (4.8) 14 (8.6)  
 Non-Western 1 (3.4) 91 (15.2) 21 (13.0)  
Maternal smoking in pregnancy, (n, %) 0 (0.0) 110 (16.4) 21 (12.6) < .001
History of chronic hypertension, (n, %) 2 (6.9) 28 (4.2) 1 (0.6) .04
History of hypertensive disease in previous pregnancy, (n, %) 0 (0.0) 49 (11.4) 3 (4.6) .09
Data are presented as mean ± SD or as number (percentage of total).
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increase, it is reasonable to assume that the aldosterone in-
crease is indeed largely due to RAS activation. Therefore, 
the renin increase in relation to CL number is likely to be 
real, and not the simple consequence of in vitro prorenin 
activation. In fact, renin increases in pregnancy are well es-
tablished (34), although information on such increases in 
early pregnancy is scarce. Renin increases are more modest 
in women with preeclampsia, a condition that is known to 
occur more often in the 0 CL group (14, 35). Given that 
the CL releases largely, if not exclusively, prorenin (31), any 
change in renin must originate in the kidney. To what de-
gree the ovarian prorenin release and the renal renin regu-
lation are related is currently unknown.
Prorenin release from the CL is known to be driven by 
hCG (30, 32). This likely explains the larger increase in 
prorenin with hMG (which contains hCG, in addition to 
FSH and LH) compared with rhFSH. Yet, hMG also af-
fected renin and aldosterone much more strongly than 
rhFSH. Why these effects could still be seen at 9 and 11 
weeks after stimulation cannot be concluded from this 
study. Possibly, the changes induced by hCG, FSH, and/or 
LH on RAAS component expression involve long-lasting 
induced epigenetic effects, with perhaps a dose-dependent 
effect of hCG on DNA methyl transferase protein expres-
sion after COS (36, 37).
Prorenin is synthesized by theca cells (38). The theca 
endocrine and vascular cells develop into the granulosa 
cell layer, which underlies the formation of the CL (39). 
This might explain why we observed a positive associ-
ation between prorenin levels and total follicle diameter 
at 11 weeks. Importantly, this association was not sig-
nificant in women with PCOS, most likely because their 
follicles are known to function aberrantly (40). In add-
ition to prorenin, the CL also synthesizes estradiol and 
progesterone, and it is the sole secretor of relaxin in early 
pregnancy (11). From this perspective it is not surprising 
that prorenin levels correlated positively with the levels 
both of relaxin and progesterone. In fact, relaxin has been 
reported to be a direct stimulator of prorenin synthesis 
and release (41). Moreover, as a potent vasodilator, cap-
able of increasing glomerular filtration (5), relaxin would 
also be expected to activate the circulating RAS, thus ex-
plaining its relationship with the levels of renin. Similarly, 
progesterone, an inhibitor of the sodium-retaining ef-
fects of aldosterone, is thought to increase renin secretion 
(42). In contrast, estradiol is a well-known stimulator of 
angiotensinogen (43). Consequently, given the inverse re-
lationship between angiotensinogen and renin, no positive 
correlation between estradiol and renin would be ex-
pected. Yet, when simultaneously considering the increase 
in angiotensinogen by comparing plasma renin activity 
(which reflects renin plus angiotensinogen) and estradiol 
in pregnant women, a positive relationship can be ob-
served (42).
The exact role of prorenin in pregnancy and in the ovary 
in particular remains elusive. Although binding to the (pro)
renin receptor initially has been suggested to allow prorenin 
to display activity, more recent studies demonstrated that 
such interaction required prorenin concentrations that are 
unlikely to ever occur in humans (44). Hence to what de-
gree prorenin truly determines ovarian angiotensin gener-
ation is still unknown.
Women with PCOS display increased prorenin levels 
(45). This might be due to enhanced thecal activity, either 
as a result of the elevated LH levels in this condition (46) 
or an increased sensitivity of thecal cells to gonadotropins 
(47, 48). We were able to confirm PCOS as a determinant 
of plasma prorenin levels, and this was also true for AMH, 
an important biomarker in PCOS diagnostics. This likely 
relates to the fact that AMH, produced by follicular 
granulosa cells, has emerged as a promising biomarker of 
ovarian reserve and “reproductive age,” correlating with 
follicle count (49, 50). Nevertheless, when analyzing PCOS 
and AMH together in a multiple regression model, only 
AMH remained an independent determinant of circulating 
prorenin.
Remarkably, preconception BMI associated negatively 
with prorenin. Because this relation was not observed in 
Table 5. Hypertensive disorders of pregnancy stratified by corpus luteum category for participants in the Predict Study, 
January 2012 to December 2016 (n = 868)
Hypertensive disorder of pregnancy 0 CL (n = 29) 1 CL (n = 672) >1 CL (n = 167) P
Gestational hypertension 6 (20.7) 50 (7.4) 6 (3.6) .007
Preeclampsia 5 (17.2) 33 (4.9) 5 (3.0) .008
 Early-onset preeclampsia (< 34 wks’ GA) 1 (20.0) 12 (36.4) 1 (20.0) .89
HELLP syndrome 1 (3.4) 2 (0.3) 0 .02
Chronic hypertension with superimposed preeclampsia 0 11 (1.7) 1 (0.6) .50
Eclampsia 1 (3.4) 2 (0.3) 0 .02
Data are presented for singleton live births in number of pregnancies (percentage of total). Chi-square test was performed.
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nonpregnant women (51), it may be pregnancy specific. 
A  logical link would be adipocyte-derived leptin, which 
upregulates aldosterone (thereby suppressing RAS activa-
tion) (52), but differences in diet, oxidative stress, or epi-
genetics need to be considered as well (53, 54). Indeed, the 
RAAS regulates angiogenesis and vasculogenesis, which 
are major features of reproduction, known to be affected 
by epigenetic pathways (55, 56). Moreover, angiotensin 
II induces oxidative stress, and this affects “reproductive 
aging,” a strong determinant of ovarian (endocrine) health 
(57). From this point of view, it is not surprising that BMI 
in a multiple regression model no longer remained an in-
dependent determinant of prorenin. This model did sup-
port a positive association between prorenin and age. This 
has been noted before (51). An additional explanation of 
this association in the present population might be that 
women of advanced reproductive age present earlier 
with infertility, requiring prorenin-upregulating COS 
treatment.
We show in the Predict cohort that pregnancies con-
ceived in the absence of a CL were more disposed to de-
velop preeclampsia, which confirms the data of the POFI 
cohort (14). It is important to note that RAAS activity 
is known to be suppressed in this condition (26, 35). Of 
interest, the 7 women in the Predict Study who later de-
veloped preeclampsia already at 9 weeks of gestation dis-
played the lowest renin/total renin ratios. This suggests that 
the RAAS suppression in preeclampsia might originate very 
early in pregnancy (35).
The strength of this study is its longitudinal 
periconceptional design, resulting in identical observa-
tions in 2 tertiary referral hospitals in the United States and 
the Netherlands, despite differences in the underlying re-
productive disorders, fertility treatment, and patient char-
acteristics. To the best of our knowledge, our study is the 
largest reporting RAAS determinants concentrations in 
early pregnancy. It demonstrates that prorenin release de-
pends on CL number and total follicle diameter, and cor-
relates with the circulating progesterone and relaxin levels. 
It raises the possibility that the type of ovarian stimula-
tion, PCOS, AMH, and BMI are additional determinants 
of RAAS activation in pregnancy. Nevertheless, it does not 
allow conclusions on the exact contribution of prorenin. 
A further limitation is that, given the nature of our partici-
pants, the study denotes a high internal and low generaliz-
ability (ie, external validity). Residual confounding cannot 
be excluded entirely. Future studies should now expand 
the current patient numbers and study RAAS alterations 
in relation to maternal cardiovascular, renal, osmoregula-
tory, and volume (mal)adaptation parameters, and indica-
tors of placental development and fetal growth. Ultimately, 
such understanding might allow us to induce the degree of 
RAAS activation that is optimal for the individual pregnant 
woman, making use of highly personalized IVF protocols.
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